The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics

被引：5
|
作者：
Mori, Masanori [1 ]
Sprague, Julian [1 ]
机构：
[1] Univ Vermont, Coll Med, Dept Med, Div Hematol & Oncol, Burlington, VT 05405 USA
来源：
LEUKEMIA RESEARCH | 2012年 / 36卷 / 01期
关键词：
ACUTE MYELOID-LEUKEMIA; FLT3;
D O I：
10.1016/j.leukres.2011.09.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E1 / E3
页数：3
相关论文
共 50 条
  • [1] The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia
    Yue, Yanhua
    Jin, Song
    Xu, Ting
    Zhou, Jin
    Ma, Liang
    Shen, Hongjie
    Wu, Depei
    Chen, Suning
    Miao, Miao
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2016, 32 : S38 - S40
  • [2] The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia
    Yanhua Yue
    Song Jin
    Ting Xu
    Jin Zhou
    Liang Ma
    Hongjie Shen
    Depei Wu
    Suning Chen
    Miao Miao
    Indian Journal of Hematology and Blood Transfusion, 2016, 32 : 38 - 40
  • [3] Successful Treatment with Gilteritinib for FLT3-ITD-positive Refractory Acute Myeloid Leukemia in a Pediatric Patient
    Fujita, Naoto
    Tamura, Yumi
    Shiraishi, Yasutaka
    Tsuboi, Ayana
    Ohno, Norioki
    Miki, Mizuka
    Chijimatsu, Ikue
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S11 - S11
  • [4] Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
    Oran, Betul
    Cortes, Jorge
    Beitinjaneh, Amer
    Chen, Hsiang-Chun
    de Lima, Marcos
    Patel, Keyur
    Ravandi, Farhad
    Wang, Xuemei
    Brandt, Mark
    Andersson, Borje S.
    Ciurea, Stefan
    Santos, Fabio R.
    Silva, Leandro de Padua
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Kantarjian, Hagop
    Borthakur, Gautam
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) : 1218 - 1226
  • [5] Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia
    Kakiuchi, Seiji
    Yakushijin, Kimikazu
    Sakai, Rina
    Kawaguchi, Koji
    Higashime, Ako
    Kurata, Keiji
    Ichikawa, Hiroya
    Nagao, Shigeki
    Rikitake, Junpei
    Kiyota, Naomi
    Matsuoka, Hiroshi
    Minami, Hironobu
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (08) : 2010 - 2015
  • [6] LONG-TERM COMPLETE REMISSION OF ACUTE LEUKEMIA
    BERNARD, J
    JACQUILL.C
    SEMAINE DES HOPITAUX, 1973, 49 (13): : 964 - &
  • [7] Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
    K D Cummins
    S M Jane
    S Ninkovic
    A Bazargan
    R Filshie
    G Sutrave
    M Hertzberg
    A Scott
    S Lane
    C K Yannakou
    D Ritchie
    J D'Rozario
    J Black
    K Bavishi
    A Wei
    Blood Cancer Journal, 2014, 4 : e237 - e237
  • [8] Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
    Cummins, K. D.
    Jane, S. M.
    Ninkovic, S.
    Bazargan, A.
    Filshie, R.
    Sutrave, G.
    Hertzberg, M.
    Scott, A.
    Lane, S.
    Yannakou, C. K.
    Ritchie, D.
    D'Rozario, J.
    Black, J.
    Bavishi, K.
    Wei, A.
    BLOOD CANCER JOURNAL, 2014, 4 : e237 - e237
  • [9] Long-term outcome of sorafenib treatment in FLT3-ITD-positive acute myeloid leukemia patients relapsing after allogeneic stem cell transplantation
    Metzelder, S. K.
    Schroeder, T.
    Luebbert, M.
    Goetze, K.
    Scholl, S.
    Ditschkowski, M.
    Meyer, R. G.
    Dreger, P.
    Basara, N.
    Fey, M.
    Salih, H.
    Finck, A.
    Finke, J.
    Pabst, T.
    Giagounidis, A.
    Neubauer, A.
    Burchert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 110 - 110
  • [10] Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
    Denise Wolleschak
    Enrico Schalk
    Christian Krogel
    Tina M Schnoeder
    Helga Luehr
    Kathleen Jentsch-Ullrich
    Thomas Fischer
    Florian H Heidel
    Journal of Hematology & Oncology, 6
12345